血府逐瘀汤调节TLR4/MyD88/NF-κB信号通路对COPD患者的抗炎作用观察

Xuefu Zhuyu Tang Regulates TLR4/MyD88/NF-κB Observation on the anti-inflammatory effect of B signaling pathway on COPD patients

关键词:  血府逐瘀汤  Toll样受体4  髓样分化因子88  核转录因子-κB  慢性阻塞性肺疾病  

Key words:  Xuefu Zhuyu Tang  Toll like receptor 4  Medullary differentiation factor 88  Nuclear transcription factor-κB,  Chronic obstructive pulmonary disease

摘要:

目的 探讨血府逐瘀汤调节Toll样受体4(TLR4)/髓样分化因子88(MyD88)/核转录因子-κB(NF-κB)信号通路对慢性阻塞性肺疾病(COPD)患者的抗炎作用。方法 选取本院2021年1月至2023年1月收治的100例COPD患者,采用随机数表法分为观察组和对照组,各50例。对照组给予常规对症治疗,观察组在对照组基础上联合血府逐瘀汤。比较两组临床疗效,同时评估其中医证候积分,另外检测两组TLR/NF-κB信号通路表达情况以及炎性因子指标[肿瘤坏死因子(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)],最后观察记录不良反应的发生情况。结果 观察组总有效率96.00%显著高于对照组84.00%,差异有统计学意义(P＜0.05)；两组治疗后咳嗽、喘息气急、咳痰、失眠多梦、舌紫暗、脉濡滑评分显著低于治疗前,差异有统计学意义(P＜0.05),观察组治疗后咳嗽、喘息气急、咳痰、失眠多梦、舌紫暗、脉濡滑评分显著低于对照组,差异有统计学意义(P＜0.05)；两组治疗后TLR4 mRNA、MYD88 mRNA、NF-κB mRNA表达显著低于治疗前,差异有统计学意义(P＜0.05),观察组治疗后TLR4 mRNA、MYD88 mRNA、NF-κB mRNA表达显著低于对照组,差异有统计学意义(P＜0.05)；两组治疗后TNF-α、IL-1β、IL-6指标显著低于治疗前,差异有统计学意义(P＜0.05),观察组治疗后TNF-α、IL-1β、IL-6指标显著低于对照组,差异有统计学意义(P＜0.05)；两组不良反应总发生率比较差异无统计学意义(P＞0.05)。结论 血府逐瘀汤用于治疗COPD疗效显著,不仅能有效改善患者临床症状,还能通过调节患者TLR4/MyD88/NF-κB信号通路表达来改善其炎症反应,安全性较高。

Abstract:

Objective To explore the regulation of Toll like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear transcription factor by Xuefu Zhuyu Tang- κB (NF-κB) The anti-inflammatory effect of signaling pathways on patients with chronic obstructive pulmonary disease (COPD). Method 100 COPD patients admitted to our hospital from January 2021 to January 2023 were selected and randomly divided into an observation group and a control group using a random number table method, with 50 patients in each group. The control group was given routine Symptomatic treatment, and the observation group was combined with Xuefu Zhuyu Decoction on the basis of the control group. Compare the clinical efficacy of two groups, evaluate their TCM syndrome scores, and test the TLR/NF-κB signaling pathway expression and inflammatory factor indicators [tumor necrosis factor (TNF-α)、 Interleukin-1 β (IL-1 β)、 Interleukin 6 (IL-6)], and finally observe and record the occurrence of adverse reactions. Results The total effective rate of 96.00% in the observation group was significantly higher than 84.00% in the control group, with a statistically significant difference (P<0.05); After treatment, the scores of cough, wheezing, dyspnea, expectoration, insomnia and dreaminess, tongue dullness, and pulse smoothness in the two groups were significantly lower than before treatment, with a statistically significant difference (P<0.05). The scores of cough, wheezing, dyspnea, expectoration, insomnia and dreaminess, tongue dullness, and pulse smoothness in the observation group were significantly lower than those in the control group, with a statistically significant difference (P<0.05); Two groups of TLR4 mRNA, MYD88 mRNA, NF after treatment- κ The expression of B mRNA was significantly lower than before treatment, and the difference was statistically significant (P<0.05). In the observation group, TLR4 mRNA, MYD88 mRNA, NF were detected after treatment- κ The expression of B mRNA was significantly lower than that of the control group, with a statistically significant difference (P<0.05); TNF after two groups of treatment- α、 IL-1 β、 The IL-6 index was significantly lower than before treatment, and the difference was statistically significant (P<0.05). The observation group had TNF after treatment- α、 IL-1 β、 The IL-6 index was significantly lower than the control group, and the difference was statistically significant (P<0.05); There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Xuefu Zhuyu Tang has a significant therapeutic effect on COPD, which not only effectively improves clinical symptoms but also regulates TLR4/MyD88/NF-κB signaling pathway expression to improve its inflammatory respons. and has high safety.